- Home
- CHY vs GERN Comparison
CHY vs GERN Comparison
Compare CHY & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHY
- GERN
- Stock Information
- Founded
- CHY 2003
- GERN 1990
- Country
- CHY United States
- GERN United States
- Employees
- CHY N/A
- GERN N/A
- Industry
- CHY Investment Managers
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- CHY Finance
- GERN Health Care
- Exchange
- CHY Nasdaq
- GERN Nasdaq
- Market Cap
- CHY 839.8M
- GERN 700.6M
- IPO Year
- CHY N/A
- GERN 1996
- Fundamental
- Price
- CHY $10.89
- GERN $1.46
- Analyst Decision
- CHY
- GERN Buy
- Analyst Count
- CHY 0
- GERN 8
- Target Price
- CHY N/A
- GERN $3.71
- AVG Volume (30 Days)
- CHY 128.3K
- GERN 12.0M
- Earning Date
- CHY 01-01-0001
- GERN 08-06-2025
- Dividend Yield
- CHY 10.11%
- GERN N/A
- EPS Growth
- CHY N/A
- GERN N/A
- EPS
- CHY N/A
- GERN N/A
- Revenue
- CHY N/A
- GERN $164,447,000.00
- Revenue This Year
- CHY N/A
- GERN $159.14
- Revenue Next Year
- CHY N/A
- GERN $52.76
- P/E Ratio
- CHY N/A
- GERN N/A
- Revenue Growth
- CHY N/A
- GERN 11877.20
- 52 Week Low
- CHY $9.97
- GERN $1.09
- 52 Week High
- CHY $12.16
- GERN $4.83
- Technical
- Relative Strength Index (RSI)
- CHY 50.55
- GERN 59.63
- Support Level
- CHY $10.65
- GERN $1.26
- Resistance Level
- CHY $10.98
- GERN $1.55
- Average True Range (ATR)
- CHY 0.12
- GERN 0.09
- MACD
- CHY -0.02
- GERN 0.02
- Stochastic Oscillator
- CHY 64.86
- GERN 75.00
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.